A New Specimen Matrix: What Must Be Bridged Before Reusing an IVD Claim?
Adding an IVD specimen matrix? Map extraction, detection and clinical evidence to each configuration, then assess the bridge and regulatory change separately.
What changes when the specimen matrix changes?
A collection label, a qualified specimen supplier and a supported storage interval do not establish that an in vitro diagnostic (IVD) performance claim transfers to another specimen matrix. Define the proposed specimen, collection device or additive, handling, extraction and detection configuration. Then identify which existing evidence covers that configuration, which relationships need a justified bridge and which gaps need new studies. A successful evidence assessment and permission to expand a marketed claim are separate decisions.
Consider a hypothetical manufacturer whose cleared multiplex respiratory assay covers nasopharyngeal (NP) swabs in a specified transport medium. It wants to add anterior nasal swabs or saliva. No assay file or study results are supplied here, so neither candidate can be declared equivalent, suitable or ready for labeling. The worksheet below shows how to reach a documented decision; it does not recommend substituting specimens in patient testing.
For this review, distinguish the biological specimen type from the matrix surrounding the target analyte. A different collection site, additive or processing step can change the configuration even when the assay reagents stay the same. MDIC’s 2019 clinical-evidence framework addresses specimen-type comparison and matrix effects separately in section 2.1.1. This article applies that distinction to evidence reuse.
Specimen and collection: record the anatomical source, device, additive or transport medium and intended-use population. Treat each proposed combination as a separate configuration until its evidence relationship is established.
Handling and preparation: record the proposed storage, transport and processing conditions, including any change before extraction. Do not leave a choice of media or pretreatments unresolved while assessing a single configuration.
Extraction and detection: identify the extraction method, assay version, analytes, result categories and control interpretation. The bridge must support the claimed result for the specified configuration.
Supplier qualification concerns the suitability of incoming materials; biological specimen sourcing covers that separate task. A specimen stability study addresses defined handling and holding conditions. Neither finding alone answers whether extraction and detection performance supports another specimen claim. That separation is an editorial inference from the configuration-specific evidence discussed below.
Decide whether you need equivalence or suitability
The public scope of CLSI EP35, second edition distinguishes clinically equivalent performance for similar-matrix specimen types from suitable performance for dissimilar matrices. It covers qualitative and quantitative procedures and explains that full validation need not necessarily be repeated for every specimen type. The edition was published on March 3, 2025; its catalog also links a correction notice.
This distinction does not classify every pair of specimens for you. Identical transport medium does not, by itself, make NP and anterior nasal specimens clinically interchangeable. Conversely, a dissimilar matrix is not automatically unsuitable. State the proposed assertion and the performance goals that would make it useful for the intended clinical purpose before deciding what evidence could support it.
EP35 assumes adequate clinical information is available to establish risk-based clinical performance goals. Establishing those goals and studying preanalytical differences are outside its scope. This article uses the public abstract and scope, not the detailed paid protocol; it does not attribute a specimen minimum, equivalence margin or specific respiratory bridge design to EP35.
MDIC likewise describes specimen-equivalency studies as an alternative to performing every validation study in every specimen type, while recognizing that some tests need complete assessment by type. Its framework is nonbinding consortium advice. Together, these sources support a reasoned assessment rather than an automatic choice between copying the old claim and repeating the entire program.
Map the extraction-to-detection evidence for each matrix
Use one worksheet for each exact candidate configuration. Here Candidate A means anterior nasal swabs in one specified collection and transport configuration; Candidate B means saliva in one specified collection and processing configuration. The baseline is the hypothetical NP claim. Tube identity, volumes, assay settings and study references must come from the manufacturer’s records. None is invented below.
The map is an editorial review tool, not a regulator-mandated form. In each row, enter the analyte and claimed result, baseline report identifier and version, matching or changed conditions, direct candidate evidence, rationale, remaining gap and next action. The authority column identifies relevant source scope; it does not establish that a candidate has met it.
| Evidence row and claimed result | Baseline record to locate | Candidate A / Candidate B: conditions to resolve | Direct evidence and bridge rationale to enter | Authority and limits | Current disposition and next action |
|---|---|---|---|---|---|
| Specimen and collection definition | Cleared claim wording and records identifying the NP specimen, collection device, medium and handling. | A: specify the anterior nasal configuration. B: specify the saliva container, additives and processing. Record the intended population for each. | Identify exactly what matches the baseline and what changes. Explain how the existing record covers the proposed claim, or identify the missing support. | FDA 2009 RVP guidance, sections 5.A and 6.A.i, within its device scope. EP35 does not cover preanalytical differences. | Unassessed for both candidates. Freeze each configuration before assigning evidence coverage. |
| Extraction quantity, quality and reproducibility | Report references for the baseline extraction method and its performance in the claimed specimen. | A and B: identify input preparation, extraction method and any changed steps; do not infer coverage from unchanged reagents. | Enter direct candidate results and the relationship to baseline performance. Explain any pooling or separate analysis rather than assuming equivalence. | FDA RVP section 6.A.iii. Significant performance differences between extraction methods can require separate clinical-data analysis. | Gap pending records and data review. Determine what candidate extraction evidence is needed. |
| Analyte-specific limit of detection (LoD) | Baseline LoD reports, targets, tested matrices and whole-process coverage. | A and B: identify each claimed analyte and the candidate matrix that reaches extraction and detection. | Record direct evidence and any rationale for consolidating full-range work. Explain why selected matrices address common and problematic conditions. | FDA RVP section 6.B.i allows assay-dependent consolidation; it does not automatically qualify either candidate. | Unassessed. Establish justified analyte/specimen coverage and resolve missing evidence without inventing replicate counts. |
| Matrix-appropriate interference and specificity | Baseline challenge studies, tested matrix, challenge rationale and affected reported results. | A and B: assess which specimen-associated substances or organisms change the challenge question. | Identify retained coverage, direct candidate testing and any remaining matrix-specific challenge gaps. | FDA RVP section 6.B.iii recommends studies in matrix equivalent to claimed specimens; MM03 provides general molecular-method context. | Gap until challenge relevance is reviewed. Do not transfer a clean baseline result without its matrix rationale. |
| Cutoff, controls and invalid-result interpretation | Assay version, interpretation rules, control criteria and relevant performance reports. | A and B: determine whether existing rules remain supported in the candidate configuration. Record proposed changes separately. | Enter control and result evidence, including invalid/retest observations where relevant. Do not assume a universal acceptable invalid rate. | FDA RVP sections 5.D–5.E and 6.A address controls, interpretation and specimen adequacy. | Unassessed. Identify evidence supporting the proposed rules and escalate any rule change for regulatory assessment. |
| Specimen stability as a dependency | Reports for the exact baseline collection, handling, transport and storage claim. | A and B: identify which conditions match and which new conditions lack support. | Reference applicable candidate stability data or a justified bridge. Keep the stability conclusion separate from detection-performance conclusions. | FDA RVP sections 6.A.i–ii. EP35’s scope does not supply the missing preanalytical studies. | Gap where the new configuration is uncovered. Resolve those conditions without assigning a generic hold time. |
| Native clinical material and comparator | Clinical report identifiers, represented matrices and populations, comparator status and analysis plan. | A and B: identify candidate clinical specimens and whether their configuration and population match the intended claim. | Record direct clinical evidence, characterize surrogate/native relationships where used, and justify remaining study needs. | FDA RVP section 6.D.v; FDA 2007 statistical guidance for qualitative reporting; MDIC section 2.1.1 for surrogate relationships. | Unassessed. Bench findings alone do not fill an absent account of candidate clinical performance. |
Use three working dispositions: covered by identified evidence; bridge proposed or in progress; unresolved gap. A proposed bridge becomes covered only after its rationale and evidence have been evaluated against justified goals. Record the report reference, conclusion, reviewer and next action so the disposition can be checked. These labels organize the review; they are not regulatory findings.
For example, finding a baseline extraction report changes an empty record cell into an identified source of evidence. It does not yet establish that its specimens represent Candidate A. Likewise, a completed saliva stability study can close the handling row while the LoD and clinical rows remain unresolved. Keep those partial conclusions visible instead of giving the entire matrix one premature pass/fail label.
Read the existing studies without overstating their reach
The FDA respiratory viral panel guidance was issued October 9, 2009 for the device type described in its scope. Its recommendations are not a universal protocol for all IVDs or every newer respiratory panel. Special-control issues must be addressed, but the document permits equivalent alternative assurances. Confirm the actual device classification and applicable controls before borrowing its study examples.
A useful qualification appears in section 6.B.i: full-range LoD determinations need not necessarily be separate for every specimen type, depending on the assay, while at least common and problematic types should be addressed. This supports considering consolidation; it does not establish that an anterior nasal specimen qualifies or that saliva necessarily requires every study to be repeated.
Section 6.A.iii addresses extraction-dependent performance, and section 6.D.v recommends clinical material from claimed matrices with statistically justified sample sizes. Read those provisions together when deciding which old reports can support a new claim. The analytical performance guide covers broader study characteristics; this map instead asks where each existing report applies.
MDIC prefers native patient specimens and allows surrogate samples when their performance relationship to patient specimens has been characterized and understood. A spike-in experiment therefore needs a stated purpose and a defensible relationship to the clinical question it supports. It is neither worthless nor proof of every aspect of a new claim.
The public CLSI MM03 catalog describes general molecular infectious-disease testing topics, including inhibitors, interfering substances and false-positive control. CLSI identifies it as archived, no longer undergoing consensus review, but retained as technically valid. Its catalog is background context, not a detailed matrix-bridging protocol or proof of current regulatory acceptance. For the narrower challenge-role question, see inclusivity and cross-reactivity.
Match EU examples to their annex and exceptions
The cited original Official Journal text of Commission Implementing Regulation (EU) 2022/1107 lays down common specifications (CS) for specified class D IVDs and states application from July 25, 2024. The examples below retain that text’s annex boundaries. They are not generic specimen-bridging sample-size rules; confirm the operative provisions for the particular device.
| Original-text provision | Scope and specified evidence | Boundary to preserve |
|---|---|---|
| Annex I, Part I, item 6 | Covered Annex II–XIII plasma devices: verify all indicated anticoagulants using at least 50 plasma specimens; infectious-agent devices use 25 positive and 25 negative. | The wording does not state a separate 50-specimen minimum per anticoagulant. It does not establish a universal IVD bridge. |
| Annex I, Part II, items 14 and 21 | Covered Annex III–XIII devices intended for serum and plasma: demonstrate equivalency with at least 25 positive donations (item 14) and 25 negative donations (item 21). | Keep the serum/plasma intended-use condition and Part II scope attached to these counts. |
| Annex I, Part II, items 10 and 17 | Covered other-body-fluid devices: comparison using specimens from the same individuals in the candidate and respective serum/plasma device. | Footnote 1 excludes Annex XIII Tables 4–6: SARS-CoV-2 antigen tests, RNA NAT devices and antigen self-tests. |
| Annex I, Part I, item 3 | Resolve discrepant results as far as possible using the specified investigative approaches. | The “as far as possible” qualification matters. Investigation does not justify the biased revision of a primary comparison warned against by FDA. |
The footnote prevents applying those other-body-fluid serum/plasma clauses to a SARS-CoV-2 NAT example. It does not establish the suitability of saliva, waive other performance evidence or decide requirements for every respiratory pathogen. Read an exception as a limit on the named provision, not as a blanket exemption for a new claim.
Comparable results still need an appropriate comparator
FDA clearance alone does not establish that a comparator is a reference standard for the target condition. For qualitative comparisons with a non-reference method, FDA’s March 13, 2007 statistical guidance recommends positive percent agreement (PPA), negative percent agreement (NPA) and confidence intervals. Agreement describes the comparison, not established diagnostic accuracy. This is nonbinding reporting guidance.
Investigate discordances without selectively replacing original comparator calls to improve primary estimates. Keep follow-up findings separate; the detailed reporting method belongs in the discordant IVD results guide. The specimen-portability worksheet does not replace that analysis plan.
Different matrices can nevertheless perform comparably. Butler-Laporte and colleagues’ 2021 systematic review found similar saliva and NP NAAT accuracy for SARS-CoV-2, particularly in ambulatory settings, using a model that allowed an imperfect reference test. This is historical, heterogeneous early-pandemic evidence, with hospitalized and critically ill patients underrepresented. It does not validate the hypothetical assay or prove formal equivalence for its proposed specimen claim. No pooled performance estimate from that review is used here as an acceptance criterion.
Close the evidence gaps before expanding the claim
Take the completed map to two separate decisions: whether evidence supports the exact claim, and what market-specific regulatory steps the change requires. Preserve both conclusions and their supporting records. A favorable analytical result does not settle the submission question.
Confirm evidence coverage: reconcile each proposed specimen configuration with its reports, rationale and unresolved actions. Hold unsupported wording while the relevant gaps remain. If the planned claim changes during development, reassess the affected rows.
Complete the regulatory change assessment: consider labeling and associated technical changes together. Identify whether the applicable route calls for a submission or supports documented implementation without a new submission; do not infer either outcome from the worksheet alone.
Reconcile the release records: ensure the final claim, configuration, study conclusions, risk review and labeling describe the same change. Close the identified evidence and regulatory actions before releasing broader claims.
For applicable US cleared devices, FDA’s October 25, 2017 change guidance addresses IVD technology, engineering, performance and materials changes in section D. D1 considers operating principle; D2 considers device-specific guidance or classification provisions; D3 considers new or significantly modified risks; D4 considers unexpected safety or effectiveness findings from verification and validation. Labeling changes also need consideration.
The guidance lists specimen-type and specimen-processing changes among changes that might alter operating principle. It does not say every such change universally requires a new 510(k). A completed bridge informs the assessment; it neither guarantees a filing is unnecessary nor substitutes for one when needed. This US framework is not a PMA supplement rule, an EU change-approval algorithm or authorization for laboratories to change clinical use.
Where this evidence map stops
The FDA examples come from the 2009 respiratory-panel, 2007 statistical-reporting and 2017 device-change guidance documents. The EU table describes the cited original 2022 CS text. CLSI EP35 is a 2025 consensus guideline with a linked correction; MM03 is archived context; MDIC’s 2019 framework is consortium advice. Their authority, device scope and purpose differ. Review the applicable versions when developing the actual evidence plan.
No commercial assay file, patient dataset, completed bridge or acceptance threshold is supplied. The worksheet therefore leaves both candidate configurations unassessed. Its useful output is a traceable account of what evidence covers, what a proposed bridge must establish and what remains unresolved before the manufacturer can support a broader claim.